2022
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications 2022, 13: 3250. PMID: 35668119, PMCID: PMC9169595, DOI: 10.1038/s41467-022-30878-4.Peer-Reviewed Original ResearchConceptsHeterologous boosterSARS-CoV-2Antibody responseMRNA vaccinesMRNA vaccinationDelta variantOmicron variantType of vaccinationStrong antibody responseMRNA vaccine candidatesVaccine candidatesNeutralization potencyImmune evasionSARS-CoV.Two weeksComparable titersVaccinationVaccineTiters 10MiceOmicronWeeksWA-1LNP-mRNABoosterVariant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2
Peng L, Renauer PA, Ökten A, Fang Z, Park JJ, Zhou X, Lin Q, Dong MB, Filler R, Xiong Q, Clark P, Lin C, Wilen CB, Chen S. Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2. Cell Reports Medicine 2022, 3: 100634. PMID: 35561673, PMCID: PMC9040489, DOI: 10.1016/j.xcrm.2022.100634.Peer-Reviewed Original ResearchConceptsImmune responseImmune cell populationsSARS-CoV-2 spikeAssessment of efficacySARS-CoV-2LNP-mRNABreakthrough infectionsCD8 TImmune profilingMRNA vaccinesPotent protectionT lymphocytesNeutralization activityDelta variantAnimal modelsPotent antibodiesRepertoire diversityCell responsesAuthentic virusSystemic increaseVariant lineagesClonal expansionCell populationsCOVID-19Vaccination
2021
PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
Thura M, Ye Z, Al-Aidaroos A, Xiong Q, Ong J, Gupta A, Li J, Guo K, Ang K, Zeng Q. PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse. Communications Biology 2021, 4: 923. PMID: 34326464, PMCID: PMC8322210, DOI: 10.1038/s42003-021-02449-8.Peer-Reviewed Original ResearchConceptsTumor relapsePhase 2 clinical trialStem cell markers SOX2Cell markers SOX2Polyploid giant cancer cellsTumor removal surgeryStem-like cellsAdjuvant immunotherapyGiant cancer cellsPrimary tumorClinical trialsTumor removalCancer cell formationAnimal modelsRelapse tumorsSolid tumorsRelapseRemoval surgeryEmbryonic stem cell markers SOX2TumorsAntibody drugsCancer cellsExtensive DNA damageMetastasisCell survival